Ara-290

Overview

ARA-290 (cibinetide) is a synthetic peptide built from erythropoietin (EPO) that selectively activates the innate repair receptor. It encourages tissue repair and offers neuroprotection, but it leaves out the red-blood-cell-stimulating effect of EPO. Like most peptides, it is a research chemical requiring reconstitution and subcutaneous injection, so purity and storage matter.

Evidence Quality

The research grade is A, and unlike many peptides in this database, that rating rests partly on genuine human data, including 6 RCTs and a meta-analysis among 63 weighted studies. That makes ARA-290 one of the better-evidenced compounds here, though much of the work still centers on specific clinical populations rather than healthy users.

What the Research Shows

An observational study in 22 sarcoidosis patients with small fiber neuropathy showed significant symptom improvement on ARA 290. A second observational study in type 2 diabetes found it improved blood sugar, lipid profiles, and neuropathic pain. In mice, ARA290 eased depression-like behavior brought on by chronic stress about as well as fluoxetine, working through anti-inflammatory effects. A review highlighted its promise for the debilitating neuropathic pain caused by sarcoidosis. In rats, it produced dose-dependent, long-term relief of neuropathic pain by quieting inflammatory cell activity. And in pigs, ARA290 improved kidney function and reduced tissue damage after induced renal injury.

Dosage Notes

The clinical dose is 4 mg subcutaneously, typically three times a week. Dosing may differ in research settings.

Effectiveness

There is solid clinical-trial data backing its use in neuropathy conditions, and it works specifically through tissue-repair pathways rather than broad, scattershot effects.

Community Sentiment

Across 36 community reports, sentiment is 69% positive, 15% neutral, and 15% negative. The most-cited effects are neuropathy relief, nerve regeneration, autoimmune modulation, anti-inflammatory action, general pain relief, and sciatica relief. Reported side effects are mostly formulation quirks: peptide aggregation, adsorption to glass, and gelling.

Availability

It is mainly available through research-chemical suppliers, has been used in formal clinical trials, and is less widely stocked than many other peptides, so sourcing can be more specialized.

Bottom Line

ARA-290 stands out for having real randomized human evidence behind it, which is rare in this space. The clinical signal for neuropathy is encouraging, though it remains an unapproved research chemical and is targeted at specific conditions rather than general optimization.